Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760266 · ClinicalTrials.gov registry record · Phase 4
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 451
- Enrollment target
NCT00760266 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 451 participants.
The verdict
NCT00760266, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 451 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of initial use of a fixed dose combination of aliskiren Hydrochlorothiazide (HCTZ) compared to Hydrochlorothiazide in older population with Stage 2 systolic hypertension.
Interventions
- DRUG Aliskiren
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760266
The ClinicalTrials.gov registry entry for NCT00760266 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 451 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren is the first listed.
NCT00760266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00760266 about?
NCT00760266 is a clinical study titled "Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population". The purpose of the study is to evaluate the efficacy and safety of initial use of a fixed dose combination of aliskiren Hydrochlorothiazide (HCTZ) compared to Hydrochlorothiazide in older population with Stage 2 systolic hypertension.
What is the current status of trial NCT00760266?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 451 participants. The study started on 2008-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00760266?
The interventions under investigation include: Aliskiren (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00760266?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.